Newsroom
3D Mammograms More Powerful than 2D
In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).
Insurer Begins Huge Palliative Care Program
“Person-centered care” is the buzz phrase floating around the health care industry, and a Pacific Northwest-based giant insurer thinks it has hit the mark with a new palliative care program coming this summer.
Former ONC Chief Mostashari Heads ACO Startup
Dr. Farzad Mostashari, former head of the Office of the National Coordinator for Health Information Technology, is starting a new firm, Aledade, to help independent primary-care physicians form accountable care organizations.
Pfizer Steps into the CAR-T Immunotherapy Field With Cellectis Deal
Pfizer's deal with the French company will ensure a market share in the promising immunooncology field.
Fast Track Status for the Oncolytic Virus Treatment Being Developed by DNAtrix
The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.
Personalized Mouse TumorGrafts to Evaluate Treatment Benefits
Icahn School of Medicine at Mount Sinai and Champions Oncology have initiated a study evaluating TumorGrafts' ability to predict treatment benefit in patients with triple-negative breast cancer. A side-by-side genomic analysis of patients' tumor and TumorGraft mouse avatars, before and after treatment, will also be conducted.
Movement Toward Exchanges Faster than Anticipated
Two measures of the evolving health insurance market show that change is happening more quickly than anticipated.
Low-dose Dexamethasone with Pomalidomide Significantly Improves OS in MM
Low-dose dexamethasone with pomalidomide improved overall survival to 12.7 months, compared to 5.7 months with high-dose dexamethasone.
Lung-MAP Study Kicked-off at Multiple Hospitals in the United States
A bold new way to test cancer drugs started Monday in hundreds of hospitals around the United States.
Proteomics to Confirm Treatment Benefit in NSCLC
A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.
3 ACO Lessons from Integrated Systems
Integrated healthcare systems, with associated providers and health plans, have a leg up on implementing accountable care organizations to improve care and lower costs. Leaders from two Washington-based integrated systems shared some best practices and lessons learned for ACO success during a panel discussion Thursday at the AHIP Institute in Seattle.
Drugmakers Lash Back at Insurers in War of Words Over Rx Prices
After enduring a rhetorical bashing over the cost of hepatitis C wonder drug Sovaldi, drug manufacturers released a study this week documenting the high cost-sharing rates charged by some insurers on health plans sold through the public exchanges.
Lymphoseek Receives FDA Approval For Diagnosis of HNSCC
The FDA has approved the diagnostic agent technetium 99m tilmanocept for the detection of the spread of head and neck cancers.
Sophisticated Chest Scans in Children: Increased Risk of Heart Disease
Cutting edge technology used to image young children with heart disease increases their risk of cancer.
HHS Fights Back to Keep Expanded 340B Drug Discounts
The drug industry scored a victory last month against the Obama administration's plans to give hospitals millions of dollars in discounts through the 340B program on orphan drugs. But HHS is sticking to its position that the Patient Protection and Affordable Care Act promises breaks on the expensive drugs when they're used for non-orphan indications.
Low Cholesterol Reduces Survival in Kidney Cancer
New research suggests that a reduction in blood cholesterol might actually prove harmful in kidney cancer patients.
EHR Incentive Cash Climbs to $24B
Some 59 percent have received meaningful use Stage 1 incentives.
How Hospital Palliative Care Programs Drive Value
Americans live in one of the most medically advanced societies in human history. But sometimes, there is no cure for what ails us.
New Hope for Healthcare Costs: Cash Pricing
Negotiating cash payments with medical providers outside the managed-care realm can save a bundle.
Ventana and MedImmune to Develop a PD-L1 Assay To Aid Patient Enrollment in Immunotherapy Trials
Ventana Medical Systems, Inc. and MedImmune today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.
The Promise of Merck's Pembrolizumab in PD-L1-expressing NSCLC
Pembrolizumab was safe and effective in patients with locally advanced or metastatic non–small cell lung cancer that strongly expressed PD-L1, according to study results presented at the ASCO Annual Meeting.
U.S. House Votes to Ensure Speedier Care for Vets
The U.S. House of Representatives passed legislation that makes it easier for patients to receive VA-paid treatment from their local doctors as a way to combat the longer waits for care at Veterans Affairs facilities.
Federal Views Diverge on Proper Use of Painkillers
The recent conversation regarding the abuse of prescription drugs that provide pain relief has some federal government officials calling this epidemic a "growing national crisis". While prescriptions such as Vicodin, OxyContin and other opioid drugs help patients with chronic pain, the White House is asking doctors to curtail their use of prescription opioids.